These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 22776534)

  • 1. Predictors of remission in depression to individual and combined treatments (PReDICT): study protocol for a randomized controlled trial.
    Dunlop BW; Binder EB; Cubells JF; Goodman MM; Kelley ME; Kinkead B; Kutner M; Nemeroff CB; Newport DJ; Owens MJ; Pace TW; Ritchie JC; Rivera VA; Westen D; Craighead WE; Mayberg HS
    Trials; 2012 Jul; 13():106. PubMed ID: 22776534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol.
    Williams LM; Rush AJ; Koslow SH; Wisniewski SR; Cooper NJ; Nemeroff CB; Schatzberg AF; Gordon E
    Trials; 2011 Jan; 12():4. PubMed ID: 21208417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical milestones predict symptom remission over 6-month and choice of treatment of patients with major depressive disorder (MDD).
    Wade AG; Schlaepfer TE; Andersen HF; Kilts CD
    J Psychiatr Res; 2009 Feb; 43(5):568-75. PubMed ID: 18954875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data.
    Wade AG; Fernández JL; François C; Hansen K; Danchenko N; Despiegel N
    Pharmacoeconomics; 2008; 26(11):969-81. PubMed ID: 18850765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brain imaging predictors and the international study to predict optimized treatment for depression: study protocol for a randomized controlled trial.
    Grieve SM; Korgaonkar MS; Etkin A; Harris A; Koslow SH; Wisniewski S; Schatzberg AF; Nemeroff CB; Gordon E; Williams LM
    Trials; 2013 Jul; 14():224. PubMed ID: 23866851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Patient Preferences on Outcomes in the Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT) Study.
    Dunlop BW; Kelley ME; Aponte-Rivera V; Mletzko-Crowe T; Kinkead B; Ritchie JC; Nemeroff CB; Craighead WE; Mayberg HS;
    Am J Psychiatry; 2017 Jun; 174(6):546-556. PubMed ID: 28335624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder.
    Khan A; Bose A; Alexopoulos GS; Gommoll C; Li D; Gandhi C
    Clin Drug Investig; 2007; 27(7):481-92. PubMed ID: 17563128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
    Pigott TA; Prakash A; Arnold LM; Aaronson ST; Mallinckrodt CH; Wohlreich MM
    Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benefits of Sequentially Adding Cognitive-Behavioral Therapy or Antidepressant Medication for Adults With Nonremitting Depression.
    Dunlop BW; LoParo D; Kinkead B; Mletzko-Crowe T; Cole SP; Nemeroff CB; Mayberg HS; Craighead WE
    Am J Psychiatry; 2019 Apr; 176(4):275-286. PubMed ID: 30764648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Major Depressive Disorder in recovery and neuropsychological functioning: effects of selective serotonin reuptake inhibitor and dual inhibitor depression treatments on residual cognitive deficits in patients with Major Depressive Disorder in recovery.
    Herrera-Guzmán I; Gudayol-Ferré E; Herrera-Abarca JE; Herrera-Guzmán D; Montelongo-Pedraza P; Padrós Blázquez F; Peró-Cebollero M; Guàrdia-Olmos J
    J Affect Disord; 2010 Jun; 123(1-3):341-50. PubMed ID: 19896719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional Connectivity of the Subcallosal Cingulate Cortex And Differential Outcomes to Treatment With Cognitive-Behavioral Therapy or Antidepressant Medication for Major Depressive Disorder.
    Dunlop BW; Rajendra JK; Craighead WE; Kelley ME; McGrath CL; Choi KS; Kinkead B; Nemeroff CB; Mayberg HS
    Am J Psychiatry; 2017 Jun; 174(6):533-545. PubMed ID: 28335622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toward a neuroimaging treatment selection biomarker for major depressive disorder.
    McGrath CL; Kelley ME; Holtzheimer PE; Dunlop BW; Craighead WE; Franco AR; Craddock RC; Mayberg HS
    JAMA Psychiatry; 2013 Aug; 70(8):821-9. PubMed ID: 23760393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early symptom change prediction of remission in depression treatment.
    Katz MM; Meyers AL; Prakash A; Gaynor PJ; Houston JP
    Psychopharmacol Bull; 2009; 42(1):94-107. PubMed ID: 19204654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Shared and Unique Changes in Brain Connectivity Among Depressed Patients After Remission With Pharmacotherapy Versus Psychotherapy.
    Dunlop BW; Cha J; Choi KS; Rajendra JK; Nemeroff CB; Craighead WE; Mayberg HS
    Am J Psychiatry; 2023 Mar; 180(3):218-229. PubMed ID: 36651624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: a pooled analysis.
    Lam RW; Lönn SL; Despiégel N
    Int Clin Psychopharmacol; 2010 Jul; 25(4):199-203. PubMed ID: 20357664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential change on depressive symptom factors with antidepressant medication and cognitive behavior therapy for major depressive disorder.
    Dunlop BW; Cole SP; Nemeroff CB; Mayberg HS; Craighead WE
    J Affect Disord; 2018 Mar; 229():111-119. PubMed ID: 29306690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early vs. conventional switching of antidepressants in patients with MDD and moderate to severe pain: a double-blind randomized study.
    Romera I; Pérez V; Menchón JM; Schacht A; Papen R; Neuhauser D; Abbar M; Picard H; Gilaberte I
    J Affect Disord; 2012 Dec; 143(1-3):47-55. PubMed ID: 22858211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report.
    Bobo WV; Chen H; Trivedi MH; Stewart JW; Nierenberg AA; Fava M; Kurian BT; Warden D; Morris DW; Luther JF; Husain MM; Cook IA; Lesser IM; Kornstein SG; Wisniewski SR; Rush AJ; Shelton RC
    J Affect Disord; 2011 Oct; 133(3):467-76. PubMed ID: 21601287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort.
    Lam RW; Milev R; Rotzinger S; Andreazza AC; Blier P; Brenner C; Daskalakis ZJ; Dharsee M; Downar J; Evans KR; Farzan F; Foster JA; Frey BN; Geraci J; Giacobbe P; Feilotter HE; Hall GB; Harkness KL; Hassel S; Ismail Z; Leri F; Liotti M; MacQueen GM; McAndrews MP; Minuzzi L; Müller DJ; Parikh SV; Placenza FM; Quilty LC; Ravindran AV; Salomons TV; Soares CN; Strother SC; Turecki G; Vaccarino AL; Vila-Rodriguez F; Kennedy SH;
    BMC Psychiatry; 2016 Apr; 16():105. PubMed ID: 27084692
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.